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ABSTRACT Human diploid fibroblasts (HDFs) can be
grown in culture for a finite number of population doublings
before they cease proliferation and enter a growth-arrest state
termed replicative senescence. The retinoblastoma gene prod-
uct, Rb, expressed in these cells is hypophosphorylated. To
determine a possible mechanism by which senescent human
fibroblasts maintain a hypophosphorylated Rb, we examined
the expression levels and interaction of the Rb kinases, CDK4
and CDK6, and the cyclin-dependent kinase inhibitors p21
and p16 in senescent HDFs. Cellular p21 protein expression
increased dramatically during the final two to three passages
when the majority of cells lost their growth potential and
neared senescence but p21 levels declined in senescent HDFs.
During this period, p16 mRNA and cellular protein levels
gradually rose with the protein levels in senescent HDFs
reaching nearly 40-fold higher than early passage cells. In
senescent HDFs, p16 was shown to be complexed to both
CDK4 and CDK6. Immunodepletion analysis of p21 and p16
from the senescent cell extracts revealed that p16 is the major
CDK inhibitor for both CDK4 and CDK6 kinases. Immuno-
precipitation of CDK4 and CDK6 and their associated pro-
teins from radiolabeled extracts from senescent HDFs showed
no other CDK inhibitors. Based upon these results, we propose
that senescence is a multistep process requiring the expres-
sion of both p21 and p16. p16 up-regulation is a key event in
the terminal stages of growth arrest in senescence, which may
explain why p16 but not p21 is commonly mutated in immortal
cells and human tumors.
Growth and cell division of human diploid fibroblasts (HDFs)
in culture eventually generates a metabolically active but
nondividing population of senescent cells. During replicative
senescence, as described by Hayflick over three decades ago
(1), human embryonic fibroblasts will undergo a total of 60–80
cumulative population doublings. Two tumor suppressor
genes, the retinoblastoma gene product (Rb) and p53, have
been implicated in the induction of the senescent state.
Inactivation of p53 and Rb function by infection with simian
virus 40 (SV40), expression of human papilloma viral proteins,
E6 and E7, (2) or down-regulation of protein expression with
anti-sense oligomers extends the life span of HDFs (3). Rb is
regulated by phosphorylation, and in senescent cells it is found
in its growth-suppressing hypophosphorylated state even in the
presence of growth factors (4). Rb inactivation leads to
expression of E2F-dependent genes such as thymidine kinase,
DNA polymerase-a, cdc2, and cyclin A (5), which are not
expressed in senescent cells (6), indicating that the failure to
phosphorylate Rb is important in the growth arrest of senes-
cent cells.
Three cyclin-dependent kinases, CDK2, CDK4, and CDK6,
are involved in the phosphorylation of the Rb protein (re-
viewed in ref. 5). In senescent fibroblasts, CDK2 is catalytically
inactive and the protein down-regulated (7). CDK4 is also
reported to be down-regulated in senescent cells (8), while the
status of CDK6 has not been previously addressed. The
activating cyclins for these CDKs, cyclins D1 and E, are present
in senescent cells at similar or elevated levels relative to early
passage cells (8). A role of the CDK inhibitors in senescence
was revealed by the isolation of a cDNA of a highly expressed
message in senescent cells that encoded the CDK inhibitor, p21
(9).
In mammalian cells, two distinct families of CDK inhibitors
have been characterized, represented by two prototype CDK
inhibitors, p21 and p16. The p21 family currently includes two
related proteins, p27Kip1 and p57Kip2, and the p16 family
currently includes four related proteins: p16INK4a (also vari-
ously known as MTS1, CDK4I and CDKN2), p15INK4b (also
known as MTS2), p18INK4c, and p19INK4d (reviewed in ref. 10).
p16 was the first member of the INK4 family characterized and
was isolated based upon its interaction with and inhibition of
CDK4 (11). Subsequently, p16 was identified as the MTS1
gene representing the melanoma susceptibility locus (12).
Homozygous deletion of p16 gene expression in mice produces
normal offspring but shows an increased incidence of lympho-
mas and sarcomas (13) unlike similarly p21 expression-deleted
mice, which show no increased risk for tumor formation (14)
although mice similarly deleted for p27Kip1 expression have
multiorgan hyperplasias (15–17).
Concurrent work has recently shown an increase in p16
protein and mRNA in senescent human fibroblasts (18, 19) but
it was not determined if this up-regulation resulted in signif-
icant CDK binding. In the present study, high cellular expres-
sion of p16 protein was found in multiple strains of senescent
HDFs. Further, in a detailed analysis of the senescent process
in MRC-5 fibroblasts, elevated p16 expression followed an
increase in p21 expression. p16 was found in both CDK4 and
CDK6 complexes and was bound to the majority of the CDK4
and nearly all of the CDK6 expressed in senescent MRC-5
fibroblasts. Immunoprecipitation of CDK4 and CDK6 and
their associated proteins from radiolabeled extracts from
senescent MRC-5 fibroblasts showed no other CDK inhibitors
present, suggesting p21 and p16 are the molecules responsible
for CDK4y6 inhibition. Finally, these results suggest that the
growth arrest in senescence fibroblasts results from amultistep
process with an increase in p21 expression as cells enter
senescence followed by a sustained elevation in the level of p16
mRNA and protein.
MATERIALS AND METHODS
Cells and Culture Conditions.HDFs used in this study were
a strain of HDF from newborn foreskin, NHF1, and three
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strains from embryonic lung tissue, MRC-5, IMR-90, and
WI-38, obtained fromM. Cordiero-Stone (University of North
Carolina, Chapel Hill), American Type Culture Collection,
Olivia Pereira-Smith (Baylor College of Medicine, Houston)
and American Type Culture Collection, respectively. GM639,
an SV40 immortalized human fibroblast line, was also ob-
tained from O. Pereira-Smith. Cells were serially passaged
twice weekly at early passage and at decreasing dilution with
increasing age. Medium was changed weekly for senescent
cultures. Proliferative potential of the culture was determined
as the labeling index (LI) measured by the percentage of cells
incorporating BrdUrd following a 48-hr incubation in com-
plete medium containing 10 mm BrdUrd and was detected by
immunocytochemistry using anti-BrdUrd antibody (Becton
Dickinson catalog no. 347580). Cultures with a LI of ,5%
were considered senescent. Early passage cells were growth
inhibited by three means: (i) growth to high density (HD) with
continued cultivation for at least 3 additional days, (ii) incu-
bation in medium containing 0.2% fetal bovine serum for 48
hr (low serum, LS), or (iii) exposure to 4 Gy of gamma-
irradiation from a cesium source (Irrad).
Extract Preparation and Protein Analysis. Total cellular
protein extracts were prepared by rinsing cultures with cold
PBS, then scraping the cells directly into either 13 Laemmli
sample buffer or a small volume of cold PBSwith 1mM sodium
vanadate, and a protease cocktail consisting of 170 mgyml
phenylmethylsulfanyl f luoride, 25 mgyml leupeptin, 25 mgyml
aprotinin, 150 mgyml benzamidine, and 10 mgyml trypsin
inhibitor. For cells scraped in PBS, concentrated SDS was
added (final concentration of 1%) and the proteins were
rapidly denatured by boiling. Viscosity was reduced by soni-
cation. For extracts in PBSySDS, protein concentrations were
determined using the DC protein assay (Bio-Rad) and diluted
with sample buffer. The total number of cells per ml in the final
sample was determined by trypsinizing a companion plate and
counting on a Coulter counter. Except where noted, all
experiments represent analysis based on an equal number of
cells.
Western blots were prepared by separation of proteins using
the Laemmli discontinuous gel system, and transferred over-
night to supported nitrocellulose (Schleicher & Schuell). Pro-
teins were visualized by standard Enhanced Chemilumines-
cence protocols (Pierce). Except where noted, antibodies were
generated as polyclonal rabbit sera against peptides or bacte-
rially produced glutathione S-transferase (GST) fusion prod-
ucts and are as follows: human GST–p16, human GST–p21, rat
mitogen-activated protein (MAP) kinase (the generous gift of
John Blenis, Harvard University, Boston), human CDK4, and
human CDK6. The following commercial antibodies were used
from Santa Cruz Biotechnology (Santa Cruz, CA); cyclin D1
(Prad1), and CDK6 (C21). Films were scanned on a Silver-
scanner DTP scanner (La Cie Unlimited, Beaverton, OR).
Immunoprecipitation and Immunodepletion of Native CDK
Complexes. Native CDK complexes were prepared as detailed
(20). Supernatants were incubated overnight with anti-CDK4
or anti-CDK6 antibodies that had been preincubated with PBS
or blocking peptide (1 mgyml sera) for 1 hr. Antibody-bound
protein A pellets were washed four times at room temperature
and resuspended in 13 Laemmli sample buffer for analysis.
For radiolabeled extracts, cells were incubated for 4–6 hr with
50 mMHepes (pH 7.4) buffered Selectamine labeling medium
(GIBCOyBRL) without added cysteine or methionine but
supplemented with 10% dialyzed fetal bovine serum, 2 mM
glutamine, and 300 mCi (1 Ci 5 37 GBq) per milliliter of
[35S]cysteineymethionine (Express labeling mix, NEN).
For immunodepletion of complexes, nondenatured lysates
as described (20) were prepared from senescent MRC-5 cells,
and an aliquot was removed for analysis as the initial extract
then centrifuged. The protein pellet was resuspended in the
same volume of 13 Laemmli sample buffer. The clarified
lysate was divided and incubated for several hours with 30 ml
of protein A-agarose beads prebound with an equal volume of
either anti-p16 or anti-p21 sera, and centrifuged. The super-
natant was immunodepleted a total of three times. The ad-
sorbed protein A-agarose pellets were washed once with lysis
buffer and resuspended in 13 Laemmli buffer. Protein con-
centrations for the initial and final p16 and p21 immunode-
pleted lysates were determined and a constant amount of
protein was analyzed by Western blot for p16, p21, CDK4,
CDK6, and MAP kinase protein levels.
RNA Expression Analysis. Total RNA was isolated from
cells using TriReagent (Molecular Research Center, Cincin-
nati). RNA (20 mg) was separated on a 1.1% formaldehyde
agarose gel. The gel was transferred onto Nytran (Schleicher
& Schuell) as per standard protocols. RNA was crosslinked to
the Nytran using a Stratalinker (Stratagene). Probes were
generated using isolated coding sequence DNA from human
glyceraldehyde phosphate dehydrogenase, p16a specific frag-
ment (59 end to RcaI), and p21 (kindly provided by James
Smith, Baylor College of Medicine, Houston). Blots were
quantitated using a PhosphorImager (Molecular Dynamics).
RESULTS
p16 and p21 Expression in Senescence HDFs. Based upon
previous reports of increased expression of the CDK inhibitor
p21 in senescent cells (9), the expression of additional inhib-
itors was examined in early passage and senescent fibroblasts
of several strains of HDFs, NHF1, MRC-5, IMR-90, and
WI-38. Total cellular protein increased 3- to 5-fold in senescent
cells, which increase significantly in size (21). Therefore, we
compared young vs. senescent cells on the amount of a given
protein per cell (termed cellular level) based on the fact that
subcellular localization by immunof luorescent staining
showed p21 and p16 proteins primarily within the nucleus (22,
23), which would therefore effectively concentrate their action.
While no increase was seen for p27Kip1(data not shown), an
increase in p21 and p16 protein expression was seen in
senescent cultures relative to logarithmically growing early
passage fibroblasts (Fig. 1 A and B). The p16 protein was at
nearly undetectable levels in log phase cells but increased
dramatically upon senescence (Fig. 1A). Senescent MRC-5
cells express nearly 40-fold higher cellular p16 protein levels
per cell than early passage cells, which translates into an
10-fold increase in protein expression based upon a per-
microgram protein analysis (see Fig. 4A). The precise increase
is difficult as the basal levels are low. The magnitude of p16
expression was variable from culture to culture of senescent
cells, but senescent cells that had been maintained for ex-
tended periods of time expressed the highest levels of p16.
Further, the relative expression of p21 vs. p16 varied between
FIG. 1. p16 and p21 protein expression in proliferating and senes-
cent HDFs. Total extracts from the same number of cells from NHF1
(lanes 1 and 2), MRC-5 (lanes 3 and 4), IMR-90 (lanes 5 and 6), and
WI-38 (lanes 7 and 8) strains of HDFs were analyzed for expression
of p16 (A) and p21 (B) under conditions of log phase growth (lanes
1, 3, 5, and 7) and senescence (lanes 2, 4, 6, and 8).
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the strains analyzed with less dramatic but significant increases
in p16 levels were seen in senescent IMR-90 and WI-38.
A more detailed examination of p21 and p16 mRNA and
protein expression under different conditions of growth inhi-
bition and at increasing passage in culture was performed on
MRC-5 fibroblasts (Fig. 2). For p21, cellular protein levels
increased in HD cultures and following incubation with re-
duced or LS. Upon serial propagation, cellular p21 levels
reached a maximum during the period in which the majority of
the cells lost their growth potential (LI'20%) as shown by the
decrease in the LI and decreasing cumulative population
doublings (Remaining CPD). The p21 level then decreased as
the cells reached a LI of ,5%, although its cellular level
remained several-fold above the levels found in log phase cells
(Figs. 1, 2, and 5B). p16 protein increased modestly upon
growth to HD and upon passage to near senescence, but
reached maximal levels when p21 levels had declined and the
cells showed no remaining growth potential (Fig. 2). p16
protein levels in senescent cells reached similar cellular levels
as those expressed in an SV40-immortalized human fibroblast
line, GM639 cells (Fig. 4A, lanes 4 and 5). No significant
changes in the cellular levels of either CDK4 or CDK6 were
observed in MRC-5 fibroblasts of any age or growth-arrest
state (Fig. 2). A several-fold decrease in cellular CDK2 was
observed in senescent and serum-starved fibroblasts (data not
shown).
p16 and p21 in CDK4 and CDK6 Complexes of Senescent
MRC-5. CDK inhibitors regulate CDK activity by forming
physical complexes with CDK or CDK-cyclin complexes. To
determine which specific CDK inhibitor(s) were involved in
senescent cells, we examined the CDK4 and CDK6 complexes.
The proteins associated with CDK4 and CDK6 were deter-
mined in MRC-5 HDF extracts from growing and growth-
arrested early passage cultures and from senescent cultures.
When CDK4 was immunoprecipitated from extracts of radio-
labeled senescent cells, proteins of 36, 33, 21, and 16 kDa were
specifically coprecipitated (Fig. 3A, lane 7) representing cyclin
D1, CDK4, and the CDK inhibitors p16 and p21, respectively
(Fig. 4A, data not shown for cyclin D1). The specificity of the
immunoprecipitations was confirmed by parallel precipita-
tions with sera blocked by competing peptides. While moder-
ate levels of p21 protein were seen in the CDK4 complexes of
growth factor deprived and gamma-irradiated cells, p16 was
identified as a significantly labeled protein in growth-factor
deprived early passage cells, in senescent MRC-5 cells and in
GM639 cells (Fig. 3A). In CDK6 complexes, proteins of '90,
40, 33, and 16 kDa specifically coprecipitate with CDK6 (Fig.
3B, data not shown). The identity of the p40 and p16 bands are
FIG. 2. Growth and age related expression of cell cycle related
proteins in MRC-5 fibroblasts. Extracts representing the same number
of cells from early passage MRC-5 fibroblasts in log phase (lane 1),
arrested by growth in reduced serum (LS) (lane 2) or to HD (lane 3)
and from MRC-5 fibroblasts at increasing age in culture (lanes 4–8)
were analyzed for expression of CDK4 and CDK6, MAP kinase, cyclin
D1, the cyclin-dependent inhibitors, p21 and p16. The percentage of
the population actively undergoing DNA synthesis during the 48-hr
period before the extracts were made is shown as the LI. The degree
of senescence is shown as the number of cumulative population
doublings remaining before loss of proliferative potential (Remaining
CPD) and is denoted as late, near senescent (Near Sen) and senescent
(Sen) populations. Lanes 1–8 represent 25, 42, 43, 53, 95, 105, 115, and
100 mg of protein, respectively.
FIG. 3. Radiolabeled proteins in immunoprecipitated native
CDK4 and CDK6 complexes from MRC-5 extracts under different
growth states. Extracts from radiolabeled early passage MRC-5 fibro-
blasts logarithmically growing (lanes 1 and 2), arrested by growth in LS
(lanes 3 and 4), 20 hr after gamma irradiation (Irrad) (lanes 5 and 6),
and senescent MRC-5 cells (Sen) (lanes 7 and 8) or a SV40-
transformed immortal human fibroblast line, GM639 (lanes 9 and 10)
were immunoprecipitated under nondenaturing conditions with anti-
CDK4 (A) or anti-CDK6 (B). Specificity of the precipitations was
shown by competing the antibody with either a buffered saline solution
(2) or peptides used to generate the antibodies in PBS (1). Extracts
from the same number of cells were immunoprecipitated. Lanes 7–10
for both A and B were exposed three times longer to compensate for
differences in radiolabel incorporation between extracts.
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CDK6 and the CDK inhibitor p16, respectively, while the
identities of the other proteins are unknown. Anti-CDK6
immunoprecipitations from radiolabeled lysates revealed no
p21 protein present under any conditions analyzed although
Western analysis of the immune complex of the unlabeled
extracts prepared at the same time showed p21 in CDK6
complexes from irradiated cells (Fig. 4C). Because proliferat-
ing-cell nuclear antigen is down-regulated during senescence
(ref. 6 and data not shown), its absence in either CDK4 or
CDK6 complexes is expected for senescent MRC-5, but we
have no explanation for its absence in the early passage
extracts. No other antibody specific proteins representing
CDK4y6 inhibitors of either the INK4 or the p21 family were
seen in either the CDK4 or CDK6 radiolabeled complexes,
suggesting they play little or no role in CDK4 or CDK6
inhibition in senescent human fibroblasts.
Comparison of relative levels of inhibitors in the complexes
by Western blot analysis of unlabeled CDK complexes for p16,
p21, and the respective CDK revealed no significant differ-
ences in p21 levels associated with CDK4 between log, growth
factor-deprived, and in cells 20 hr after irradiation when
normalized to the amount of CDK4 precipitated, whereas
CDK4 complexes from MRC-5 senescent contained 75% less
p21 as compared with complexes from logarithmically growing
cells (Fig. 4). Interestingly, significant levels of p21 accumu-
lated in the CDK6 complex from irradiated cells at a time in
which no change in levels of p21 was found in the CDK4
complexes from log phase cells, reduced serum-treated and
irradiated MRC-5 fibroblasts.
Senescent CDK4 and CDK6 complexes contain 8- and
13-fold, respectively, higher amounts of p16 protein as com-
pared with logarithmically growing MRC-5s (Fig. 4). These
levels of complex-bound p16 were similar to the amounts
found in GM639 cells. No significant change of p16 levels in
complexes from either growth factor deprived or irradiated
cells was observed, although a modest increase in cellular p16
and p16yCDK4 complex was found upon growth to HD (data
not shown).
Amount of CDK4 and CDK6 Complexed with p16 and p21.
The relative contribution of p16 and p21 in inhibiting CDK4
and CDK6 in senescence was determined by quantitation of
the amounts of CDK4 and CDK6 remaining following immu-
nodepletion of p21 and p16 from nondenatured extracts. p16
depletion removed the majority of CDK4 and nearly all of the
CDK6, while p21 depletion removed some of the CDK4 and
little of the CDK6 (Fig. 5 A and B, lanes 4 and 5). When
normalized to the amount of MAP kinase present in the
immunodepleted extracts,'70% of the CDK4 and 85% of the
CDK6, were associated with p16, while complexes containing
p21 represented the remaining percentages. Removal of either
p16 or p21 did not decrease the amount of the other inhibitor
from the final extract (Fig. 5B, lanes 4–6). Further, all of the
p21, p16, CDK4, and CDK6 was solubilized by the extraction
procedure (Fig. 5B, lanes 3 and 4, data not shown for CDKs).
Expression of p16 and p21 mRNAs. Northern blot analysis
of total RNA prepared from MRC-5 cells of increasing age
revealed that p16 and p21 mRNA levels generally correlated
with the magnitude of their protein expression (Fig. 6). As two
promoters generate two p16 mRNAs (24), we used an exon 1a
specific p16 probe to detect the p16 protein specific message
(p16a mRNA). This probe hybridized primarily to a 1.1-kb
mRNA and in young cultures, p16a mRNA levels increased
'4-fold in HD cultures but not under growth factor limiting
conditions (Fig. 6A, lanes 2 and 3). Further, expression
increased with increasing age, reaching 17- and 12-fold higher
levels in two senescent cultures with an average of a 12-fold
increase in four independent samples (Fig. 6A, lanes 6 and 7,
data not shown). Hybridization with the full-length cDNA for
human p21 revealed a 2.1-kb mRNA that showed 2- to 3-fold
increases under limiting growth factor and HD conditions as
well as with increasing age but upon senescence decreased
significantly to an average of only a 1.2-fold increase in the four
independent samples, which reflects the changes seen in p21
protein expression (Figs. 2 and 6B, data not shown).
DISCUSSION
Isolation and characterization of the CDK inhibitor p21 as a
gene with increased expression in senescent human fibroblasts
(9), and its characterization as a protein that interacted with
FIG. 4. Relative levels of CDK inhibitors, p21 and p16 in total extracts and in CDK complexes in human fibroblasts. Extracts from early passage
MRC-5 fibroblasts logarithmically growing (lane 1), arrested by growth in LS (lane 2), or 20 hr after gamma irradiation (Irrad) (lane 3), and senescent
MRC-5 cells (Sen) (lanes 4) or a SV40-transformed immortal human fibroblast line, GM639 (lane 5) were either analyzed directly (Total lysates)
(A) or immunoprecipitated under nondenaturing conditions with anti-CDK4 (B) or anti-CDK6 (C) antibodies. Total and immunoprecipitated
lysates were analyzed for the levels of CDK4, CDK6, p21, and p16 present. The approximate relative levels in total extracts were determined directly
by densitometry. For immunoprecipitated extracts, relative levels were normalized for the amount of the appropriate CDK immunoprecipitated.
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and inhibited the CDKs (25, 26) initially suggested a mecha-
nism for why Rb was hypophosphorylated in senescent fibro-
blasts. Further, the finding that p21 transcription was activated
by p53 (27), suggested a mechanism through which SV40 Tag
inactivation of p53, and therefore suppression of p21 protein
levels, could extend the life span of HDFs in culture (2). In this
study we confirm that p21 expression is increased in old
MRC-5 fibroblasts, leading to a dramatic decrease in the
proliferative potential of the population. However, upon se-
nescence, p21 protein levels decreased and expression of the
INK4 family CDK inhibitor, p16, dramatically increased, sug-
gesting that p16 becomes the primary inhibitor of the Rb
kinases, CDK4 and CDK6. While Hara et al. (18), have shown
an increase in p16 mRNA and protein upon senescence, no
direct interaction between the inhibitor and the CDKs or its
relative contribution to CDK inhibition was shown. We report
here that the majority of the CDK4 and the CDK6 kinases are
complexed with p16 in senescent MRC-5 HDFs. p16 accumu-
lation after the cells have exited the cycle suggests that
additional cellular changes are ongoing during increasing time
in senescence and that cells may exist in one of multiple stages
of senescence. These results suggest an alternate model for
SV40 Tag-mediated extension of HDF lifespan in which Tag
inactivation of Rb disrupts the p16-CDK4y6-Rb growth in-
hibitory pathway.
The mechanism for the senescence-induced p16 increases is
not known. In immortalized cells, inactivation of Rb by
deletion or viral inactivation (18, 28) or by hyperphosphory-
lation as found at the G1yS boundary (29, 30) are reported to
increase p16 although the cell cycle increases are disputed (18,
24). Inactivation through hyperphosphorylation cannot ex-
plain the p16 increases, as Rb is hypophosphorylated in
senescent HDFs and expressed at similar levels relative to early
passage cells (4). One possibility is that with the inactivation of
the Rb kinases, CDK2y4y6, Rb is dephosphorylated and may
no longer interact with transcription factors that may require
partial Rb (hypo)phosphorylation for binding. Dephosphory-
lated Rb may allow the activation of p16 transcription. Alter-
natively, in senescent cells, p16 increases may result from Rb
inactivation through a yet undefined pathway involving the
activity of additional proteins interacting with Rb, as suggested
by the formation of unique senescent-specific RbyE2F and
p107yE2F complexes containing p21, cyclins, and CDK2 (31).
Further, suppression of p16 expression may require a specific
Rb-E2F complex such as E2F1 or require Rb in conjunction
with another transcriptional corepressor that may be down-
regulated upon extended growth suppression. E2F1 expression
has been shown to be down-regulated (31) or not expressed in
senescent cells (32). An additional possibility is that the p16
promoter may contain additional regions that are Rb-
independent and are activated in senescent cells possibly
through a p21-initiated mechanism. Finally, increased stability
of p16 mRNA in senescence has been reported (18) and may
explain the increased p16 mRNA levels, although this mech-
anism would have to be selective for p16.
p16 may function as a tumor suppressor through its role as
a senescence gene. The p16 gene corresponds to the melanoma
cancer gene, MTS1, on chromosome 9 (12, 33) and p16
mutations have been found inmultiple tumor types (34), unlike
the p21 gene where no mutations have been found in screens
of a wide range of tumor types (35, 36). Ablation of p16
expression by homozygous deletion in mice produces viable
offspring but leads to dramatically increased spontaneous
tumor formation and enhanced susceptibility to carcinogens.
FIG. 5. Relative amounts of CDK4 and CDK6 complexed with p16
and p21 in senescent MRC-5. Extracts of senescent MRC-5 fibroblasts
were immunodepleted for either p16 or p21 by three serial precipi-
tations with p16 and p21 antisera. The protein levels of CDK4, CDK6
and MAP kinase (A) or p16 and p21 (B) were examined. (A) Lanes
1 and 2 represent the same number of early passage and senescent cells
while lanes 3–6 represent 150 mg of the untreated (lane 3), p16-
depleted (lane 4), and p21-depleted extracts (lane 5). (B) Protein (150
mg) was analyzed for total extracts of early passage (lane 1), senescent
cells (lane 2), and untreated (lane 4), p16-depleted (lane 5) and
p21-depleted (lane 6) extracts. The extracted cell pellet was resus-
pended in a similar volume of Laemmli sample buffer and a fraction
representing the same fraction as loaded for the untreated extract
representing an undefined amount of protein (lane 3) was analyzed.
FIG. 6. Expression of p16, p21 and glyceraldehyde phosphate
dehydrogenase mRNAs in MRC-5 cells. RNA from cells in log phase
(lane 1, log), growth arrested by incubation in reduced serum (lane 2,
LS), growth arrested by growth to HD (lane 3) or from cells approach-
ing and in senescence (lanes 4 to 7, CPD Remaining) were probed for
levels of p16a (A), p21 (B), and glyceraldehyde phosphate dehydro-
genase (C) mRNAs. The LIs for the log and increasing age (lanes 1,
4–7) were 72, 49, 39, 33, and 5%, respectively. Increases are expressed
relative log phase cell expression based upon normalization to glyc-
eraldehyde phosphate dehydrogenase expression.
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The cultured embryonic fibroblasts of these mice lack the crisis
event before immortalization and are transformed by the
expression of a single oncogene (13). However, deletion of the
p16 gene also prevents the expression of an alternatively
spliced mRNA containing exons 2 and 3 in common with p16.
This mRNA produces an unrelated, 19-kDa protein that also
suppresses growth (37). In humans, a similar mRNA may
generate a 13 kDa protein (24) whose protein expression and
activity have yet to be determined. Deletion of p21 in mice also
produces viable normal offspring without any apparent phe-
notype except cells from these mice have a reduced growth-
arrest response following gamma-irradiation (14). These re-
sults suggest that both p16 and p21 are not developmental
growth regulators but checkpoint proteins, with p16 playing a
critical role in cellular immortalization and tumor prevention.
In conclusion, we have shown that replicative cellular se-
nescence of HDFs is a multistep process involving the sequen-
tial expression of p21 and p16 resulting in p16 becoming the
major CDK4yCDK6 inhibitor in senescent MRC-5 fibroblasts.
Current models explain a possible mechanism for the initiation
of p21 expression, while the mechanism of p21 down-
regulation and increased p16 expression have not been delin-
eated. Current work is focusing upon defining these pathways
and toward defining the relative roles p21 and p16 may play in
the growth arrest found in senescent fibroblasts.
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